CHMP ISSUES POSITIVE OPINION FOR FUTIBATINIB FOR THE TREATMENT OF ADULTS WITH CHOLANGIOCARCINOMA

/PRNewswire/ -- Taiho Oncology Europe GmbH and Taiho Pharmaceutical Co., Ltd. announced today that the European Medicines Agency's (EMA) Committee for...

Related Keywords

Hannover ,Niedersachsen ,Germany ,Tokyo ,Japan ,Switzerland ,Intrahepatic Cholangiocarcinoma ,Arndt Vogel ,Junko Onishi ,Europe Gmbh Zug ,Peter Foertig ,Takeshi Sagara ,Judy Kay Moore ,Europe Gmb ,Guidelines Committee ,European Union ,Hannover Medical School ,European Medicines Agency ,Department Of Gastroenterology ,Otsuka Holdings Co Ltd ,Clinical Development ,European Commission ,Taiho Pharmaceutical Co Ltd ,Committee For Medicinal Products Human Use ,Preclinical Research At Taiho ,Oncology Europe Gmbh ,Medicinal Products ,Human Use ,Vice President ,Medical Affairs ,Taiho Oncology ,New England Journal ,Professor Arndt Vogel ,Senior Consultant ,Managing Director ,Preclinical Research ,Taiho Pharmaceutical ,Taiho Oncology Europe ,Patients With Advanced Solid Tumors Harboring ,Oncology Europe Media Contact ,Pharmaceutical Media Contact ,Risk Factors ,Nature Reviews Gastroenterology ,Rearranged Intrahepatic ,Practice Guideline ,Oncology Europe ,Taiho Oncology Europe Gmbh ,